Halozyme Therapeutics Ownership 2024 | Who Owns Halozyme Therapeutics Now?


OverviewForecastRevenueFinancialsChartTranscripts

Institutional Ownership

94.57%

Insider Ownership

1.11%

Retail Ownership

4.31%

Institutional Holders

413.00

Halozyme Therapeutics Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BLACKROCK INC.14.13%0.02%18,241,548-389,415-2.09%742,066,172Mar 31, 2024
VANGUARD GROUP INC10.11%0.01%13,049,253-210,261-1.59%530,843,613Mar 31, 2024
STATE STREET CORP5.03%0.01%6,487,30311,7540.18%263,903,486Mar 31, 2024
SNYDER CAPITAL MANAGEMENT L P3.19%3.59%4,117,227407,62810.99%167,488,794Mar 31, 2024
ARTISAN PARTNERS LIMITED PARTNERSHIP2.94%0.22%3,791,230-2,897,828-43.32%154,227,236Mar 31, 2024
ALLIANCEBERNSTEIN L.P.2.84%0.05%3,666,324202,6305.85%149,146,060Mar 31, 2024
JPMORGAN CHASE & CO2.51%0.01%3,240,497146,5654.74%131,823,416Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC2.35%0.01%3,027,384107,6213.69%123,171,534Mar 31, 2024
MACQUARIE GROUP LTD2.32%0.14%2,991,125-291,515-8.88%121,679,000Mar 31, 2024
TD ASSET MANAGEMENT INC1.97%0.10%2,541,266557,35028.09%103,378,701Mar 31, 2024
GW&K INVESTMENT MANAGEMENT, LLC1.70%0.79%2,196,877-29,661-1.33%89,369,000Mar 31, 2024
INVESCO LTD.1.62%0.02%2,088,41057,7762.85%84,956,520Mar 31, 2024
ARROWMARK COLORADO HOLDINGS LLC1.44%0.85%1,858,841282,75817.94%75,617,652Mar 31, 2024
NORTHERN TRUST CORP1.39%0.01%1,791,904-181,840-9.21%72,894,654Mar 31, 2024
THRIVENT FINANCIAL FOR LUTHERANS1.33%0.14%1,714,844-206,815-10.76%69,760,000Mar 31, 2024
BANK OF AMERICA CORP /DE/1.32%0.01%1,697,152509,49342.90%69,040,143,000Mar 31, 2024
DIMENSIONAL FUND ADVISORS LP1.31%0.02%1,688,22975,1164.66%68,677,157Mar 31, 2024
CHARLES SCHWAB INVESTMENT MANAGEMENT INC1.29%0.02%1,667,479-68,643-3.95%67,833,046Mar 31, 2024
NUVEEN ASSET MANAGEMENT, LLC1.28%0.02%1,651,610126,4088.29%67,187,839Mar 31, 2024
STEPHENS INVESTMENT MANAGEMENT GROUP LLC1.20%0.84%1,546,66628,2111.86%62,918,373Mar 31, 2024

Halozyme Therapeutics's largest institutional shareholder is BLACKROCK INC., holding 14.13% of the company's total share outstanding, currently valued at $742.07M. The top 10 institutional shareholders own together 47.39% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
FUTURE FUND LLC0.01%4.05%12,2755,10971.30%499,347Mar 31, 2024
CUTTER CAPITAL MANAGEMENT, LP0.20%4.00%255,04914,6016.07%10,375,393Mar 31, 2024
SNYDER CAPITAL MANAGEMENT L P3.19%3.59%4,117,227407,62810.99%167,488,794Mar 31, 2024
BERNZOTT CAPITAL ADVISORS0.16%3.38%209,80484,82567.87%8,534,827Mar 31, 2024
KOA WEALTH MANAGEMENT, LLC0.06%2.73%74,4169,50314.64%3,027,243Mar 31, 2024
2XIDEAS AG0.40%2.57%515,462-28,704-5.27%20,968,994Mar 31, 2024
STEAMBOAT CAPITAL PARTNERS, LLC0.13%2.41%171,9492,8651.69%6,994,885Mar 31, 2024
HARVEY CAPITAL MANAGEMENT INC0.14%2.16%181,49021,38013.35%7,383,013Mar 31, 2024
MESIROW INSTITUTIONAL INVESTMENT MANAGEMENT, INC.0.28%1.32%364,047-89,780-19.78%14,809,432Mar 31, 2024
GRANITE INVESTMENT PARTNERS, LLC0.63%1.26%811,458-20,964-2.52%33,010,111Mar 31, 2024
PIER CAPITAL, LLC0.17%1.25%222,63293,15371.94%9,056,670Mar 31, 2024
PENN CAPITAL MANAGEMENT COMPANY, LLC0.21%0.99%272,596-6,944-2.48%11,130,236Mar 31, 2024
ELEQUIN SECURITIES, LLC0.21%0.99%272,596272,596100.00%11,130,236Mar 31, 2024
EFG ASSET MANAGEMENT (NORTH AMERICA) CORP.0.11%0.98%140,0899,3577.16%5,693,217Mar 31, 2024
SHAKER INVESTMENTS LLC/OH0.04%0.91%52,6831150.22%2,143,144Mar 31, 2024
REDWOOD INVESTMENTS, LLC0.06%0.91%77,306-15,744-16.92%3,100,101Mar 31, 2024
MOODY ALDRICH PARTNERS LLC0.10%0.86%123,924123,924100.00%5,041,228Mar 31, 2024
ARROWMARK COLORADO HOLDINGS LLC1.44%0.85%1,858,841282,75817.94%75,617,652Mar 31, 2024
STEPHENS INVESTMENT MANAGEMENT GROUP LLC1.20%0.84%1,546,66628,2111.86%62,918,373Mar 31, 2024
HODGES CAPITAL MANAGEMENT INC.0.25%0.82%317,045120,58061.37%12,897Mar 31, 2024

The largest Halozyme Therapeutics shareholder by % of total assets is FUTURE FUND LLC. The company owns 12.28K shares of Halozyme Therapeutics (HALO), representing 4.05% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
FIRST TRUST ADVISORS LP0.93%0.05%1,194,4641,102,6231200.58%48,590,795Mar 31, 2024
HANDELSBANKEN FONDER AB0.64%0.15%828,669582,600236.76%33,710,000Mar 31, 2024
TD ASSET MANAGEMENT INC1.97%0.10%2,541,266557,35028.09%103,378,701Mar 31, 2024
BANK OF AMERICA CORP /DE/1.32%0.01%1,697,152509,49342.90%69,040,143,000Mar 31, 2024
SNYDER CAPITAL MANAGEMENT L P3.19%3.59%4,117,227407,62810.99%167,488,794Mar 31, 2024
VOLORIDGE INVESTMENT MANAGEMENT, LLC0.31%0.06%398,306343,572627.71%16,203,088Mar 31, 2024
BALYASNY ASSET MANAGEMENT L.P.0.31%0.03%395,420298,985310.04%16,085,686Mar 31, 2024
ARROWMARK COLORADO HOLDINGS LLC1.44%0.85%1,858,841282,75817.94%75,617,652Mar 31, 2024
ELEQUIN SECURITIES, LLC0.21%0.99%272,596272,596100.00%11,130,236Mar 31, 2024
D. E. SHAW & CO., INC.0.23%0.01%298,125272,5491065.64%12,127,725Mar 31, 2024
EPOCH INVESTMENT PARTNERS, INC.1.11%0.26%1,433,612270,57923.26%58,319,336Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC0.33%0.03%431,380238,000123.07%17,549,000Mar 31, 2024
FRANKLIN RESOURCES INC0.24%0.00%307,704233,909316.97%12,517,400Mar 31, 2024
ALLIANCEBERNSTEIN L.P.2.84%0.05%3,666,324202,6305.85%149,146,060Mar 31, 2024
LOMBARD ODIER ASSET MANAGEMENT (SWITZERLAND) SA0.14%0.50%175,000175,000100.00%7,119,000Mar 31, 2024
FULLER & THALER ASSET MANAGEMENT, INC.0.44%0.10%568,361158,67938.73%23,120,908,000Mar 31, 2024
WINTON GROUP LTD0.11%0.43%148,130148,130100.00%6,025,928Mar 31, 2024
CUBIST SYSTEMATIC STRATEGIES, LLC0.25%0.07%319,296146,81785.12%12,988,971Mar 31, 2024
JPMORGAN CHASE & CO2.51%0.01%3,240,497146,5654.74%131,823,416Mar 31, 2024
NUVEEN ASSET MANAGEMENT, LLC1.28%0.02%1,651,610126,4088.29%67,187,839Mar 31, 2024

As of Mar 31 2024, Halozyme Therapeutics's largest institutional buyer is FIRST TRUST ADVISORS LP. The company purchased 1.10M stocks of HALO, valued at $48.59M.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ARTISAN PARTNERS LIMITED PARTNERSHIP2.94%0.22%3,791,230-2,897,828-43.32%154,227,236Mar 31, 2024
GOLDMAN SACHS GROUP INC0.64%0.01%821,386-720,224-46.72%33,413,982Mar 31, 2024
MARSHALL WACE, LLP0.06%0.00%75,533-570,635-88.31%3,072,683Mar 31, 2024
BLACKROCK INC.14.13%0.02%18,241,548-389,415-2.09%742,066,172Mar 31, 2024
DRIEHAUS CAPITAL MANAGEMENT LLC----331,703-100.00%-Mar 31, 2024
ENSIGN PEAK ADVISORS, INC0.03%0.00%42,668-295,932-87.40%1,735,734Mar 31, 2024
MACQUARIE GROUP LTD2.32%0.14%2,991,125-291,515-8.88%121,679,000Mar 31, 2024
EAGLE ASSET MANAGEMENT INC----232,113-100.00%-Mar 31, 2024
TWINBEECH CAPITAL LP----222,279-100.00%-Mar 31, 2024
VANGUARD GROUP INC10.11%0.01%13,049,253-210,261-1.59%530,843,613Mar 31, 2024
THRIVENT FINANCIAL FOR LUTHERANS1.33%0.14%1,714,844-206,815-10.76%69,760,000Mar 31, 2024
NORTHERN TRUST CORP1.39%0.01%1,791,904-181,840-9.21%72,894,654Mar 31, 2024
MILLENNIUM MANAGEMENT LLC0.10%0.00%132,068-178,838-57.52%5,372,526Mar 31, 2024
WOODLINE PARTNERS LP----173,808-100.00%-Mar 31, 2024
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.----159,242-100.00%-Mar 31, 2024
SEI INVESTMENTS CO0.26%0.02%329,123-151,673-31.55%13,388,674Mar 31, 2024
KENNEDY CAPITAL MANAGEMENT LLC0.40%0.43%513,096-149,720-22.59%20,872,745Mar 31, 2024
FIRST LIGHT ASSET MANAGEMENT, LLC----134,050-100.00%-Mar 31, 2024
BARCLAYS PLC0.22%0.00%284,579-126,119-30.71%11,576,000Mar 31, 2024
BAIRD FINANCIAL GROUP, INC.0.01%0.00%11,083-116,715-91.33%450,856Mar 31, 2024

As of Mar 31 2024, Halozyme Therapeutics's biggest institutional seller is ARTISAN PARTNERS LIMITED PARTNERSHIP. The company sold -2.90M shares of HALO, valued at $154.23M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
ELEQUIN SECURITIES, LLC0.21%0.99%272,596272,596100.00%11,130,236Mar 31, 2024
LOMBARD ODIER ASSET MANAGEMENT (SWITZERLAND) SA0.14%0.50%175,000175,000100.00%7,119,000Mar 31, 2024
WINTON GROUP LTD0.11%0.43%148,130148,130100.00%6,025,928Mar 31, 2024
MOODY ALDRICH PARTNERS LLC0.10%0.86%123,924123,924100.00%5,041,228Mar 31, 2024
TWO SIGMA INVESTMENTS, LP0.09%0.01%113,792113,792100.00%4,629,059Mar 31, 2024
HILLSDALE INVESTMENT MANAGEMENT INC.0.09%0.36%112,900112,900100.00%4,592,772Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.07%0.00%91,20091,200100.00%3,710,016Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.05%0.00%60,83360,833100.00%2,474,686Mar 31, 2024
TORNO CAPITAL, LLC0.04%0.13%50,00050,000100.00%2,034,000Mar 31, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.04%0.00%46,70046,700100.00%1,899,756Mar 31, 2024
ADVISORS PREFERRED, LLC0.02%0.17%24,84724,847100.00%1,026,678Mar 31, 2024
TECTONIC ADVISORS LLC0.01%0.06%18,24118,241100.00%742,044Mar 31, 2024
SHELTON WEALTH MANAGEMENT, LLC0.01%0.46%18,04018,040100.00%733,867Mar 31, 2024
COMMONWEALTH EQUITY SERVICES, LLC0.01%0.00%15,17215,172100.00%617,000Mar 31, 2024
PATHSTONE HOLDINGS, LLC0.01%0.00%13,56113,561100.00%551,661Mar 31, 2024
OAK HILL WEALTH ADVISORS, LLC0.01%0.15%11,30011,300100.00%459,684Mar 31, 2024
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)0.01%0.01%11,04211,042100.00%449,189Mar 31, 2024
UNIQUE WEALTH STRATEGIES, LLC0.01%0.22%10,94310,943100.00%445,162Mar 31, 2024
ALLIANZ ASSET MANAGEMENT GMBH0.01%0.00%10,55910,559100.00%429,540Mar 31, 2024
DIVERSIFY ADVISORY SERVICES, LLC0.01%0.02%8,3318,331100.00%344,237Mar 31, 2024
SCIENTECH RESEARCH LLC0.01%0.18%8,2148,214100.00%334,146Mar 31, 2024
0.01%0.01%8,0458,045100.00%327,276Mar 31, 2024
ZUCKERMAN INVESTMENT GROUP, LLC0.01%0.04%8,0008,000100.00%325,440Mar 31, 2024
WRAPMANAGER INC0.01%0.09%7,9497,949100.00%323,365Mar 31, 2024
JUNCTURE WEALTH STRATEGIES, LLC0.01%0.13%7,4597,459100.00%303,432Mar 31, 2024
STIFEL FINANCIAL CORP0.01%0.00%7,1337,133100.00%290,173Mar 31, 2024
ALPHA DNA INVESTMENT MANAGEMENT LLC0.01%0.10%6,6766,676100.00%271,579Mar 31, 2024
TWIN TREE MANAGEMENT, LP0.01%0.00%6,6006,600100.00%268,488Mar 31, 2024
POINT72 ASIA (SINGAPORE) PTE. LTD.0.01%0.07%6,5906,590100.00%268,066Mar 31, 2024
BALBOA WEALTH PARTNERS0.00%0.07%5,7685,768100.00%234,642Mar 31, 2024
SHEAFF BROCK INVESTMENT ADVISORS, LLC0.00%0.01%5,5405,540100.00%225,368Mar 31, 2024
RESOURCES INVESTMENT ADVISORS, LLC.0.00%0.00%5,4785,478100.00%222,845Mar 31, 2024
MML INVESTORS SERVICES, LLC0.00%0.00%5,4375,437100.00%221,000Mar 31, 2024
OLD NATIONAL BANCORP /IN/0.00%0.01%5,2075,207100.00%211,820Mar 31, 2024
CALLAN CAPITAL, LLC0.00%0.02%5,1285,128100.00%208,607Mar 31, 2024
TITLEIST ASSET MANAGEMENT, LLC0.00%0.04%5,0145,014100.00%203,970Mar 31, 2024
CIBC PRIVATE WEALTH GROUP, LLC0.00%0.00%2,8832,883100.00%119,126,000Mar 31, 2024
CENTRAL PACIFIC BANK - TRUST DIVISION0.00%0.01%2,8202,820100.00%116,522Mar 31, 2024
NVERSES CAPITAL, LLC0.00%0.18%1,8001,800100.00%73,224,000Mar 31, 2024
FIDELIS CAPITAL PARTNERS, LLC0.00%0.04%1,2841,284100.00%334,490Mar 31, 2024
WHITTIER TRUST CO0.00%0.00%672672100.00%27,336Mar 31, 2024
RISE ADVISORS, LLC0.00%0.01%611611100.00%24,855Mar 31, 2024
MATHER GROUP, LLC.0.00%0.00%205205100.00%7,577,000Mar 31, 2024
DAVIDSON CAPITAL MANAGEMENT INC.0.00%0.00%184184100.00%7,486Mar 31, 2024
MARK SHEPTOFF FINANCIAL PLANNING, LLC0.00%0.00%8585100.00%3,458Mar 31, 2024
CONTINUUM ADVISORY, LLC0.00%0.00%7171100.00%3,113,000Mar 31, 2024
VITALSTONE FINANCIAL, LLC0.00%0.00%6767100.00%3Mar 31, 2024
-0.00%4242100.00%1,832Mar 31, 2024
UMB BANK, N.A.--3838100.00%1,546Mar 31, 2024
VALLEY NATIONAL ADVISERS INC-0.00%3535100.00%1,000Mar 31, 2024
NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC--2626100.00%1,057Mar 31, 2024
CAROLINAS WEALTH CONSULTING LLC-0.00%2222100.00%913Mar 31, 2024
SMARTLEAF ASSET MANAGEMENT LLC-0.00%1616100.00%371,000Mar 31, 2024
NEWBRIDGE FINANCIAL SERVICES GROUP, INC.-0.00%1010100.00%407Mar 31, 2024

Halozyme Therapeutics's largest new institutional shareholder by number of shares is ELEQUIN SECURITIES, LLC, purchased 272.60K shares, valued at $11.13M, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
DRIEHAUS CAPITAL MANAGEMENT LLC----331,703-100.00%-Mar 31, 2024
EAGLE ASSET MANAGEMENT INC----232,113-100.00%-Mar 31, 2024
TWINBEECH CAPITAL LP----222,279-100.00%-Mar 31, 2024
WOODLINE PARTNERS LP----173,808-100.00%-Mar 31, 2024
CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD.----159,242-100.00%-Mar 31, 2024
FIRST LIGHT ASSET MANAGEMENT, LLC----134,050-100.00%-Mar 31, 2024
CASTLEARK MANAGEMENT LLC----115,894-100.00%-Mar 31, 2024
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND----105,000-100.00%-Mar 31, 2024
OBERWEIS ASSET MANAGEMENT INC/----96,300-100.00%-Mar 31, 2024
HRT FINANCIAL LP----78,318-100.00%-Mar 31, 2024
POINT72 HONG KONG LTD----56,675-100.00%-Mar 31, 2024
COWEN AND COMPANY, LLC----54,034-100.00%-Mar 31, 2024
EVOKE WEALTH, LLC----36,657-100.00%-Mar 31, 2024
SCHONFELD STRATEGIC ADVISORS LLC----34,502-100.00%-Mar 31, 2024
BAYESIAN CAPITAL MANAGEMENT, LP----31,500-100.00%-Mar 31, 2024
HIGHMARK WEALTH MANAGEMENT LLC----31,290-100.00%-Mar 31, 2024
INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC----27,868-100.00%-Mar 31, 2024
DOHENY ASSET MANAGEMENT /CA----22,578-100.00%-Mar 31, 2024
SIT INVESTMENT ASSOCIATES INC----20,225-100.00%-Mar 31, 2024
GRAHAM CAPITAL MANAGEMENT, L.P.----19,422-100.00%-Mar 31, 2024
WOLVERINE ASSET MANAGEMENT LLC----17,500-100.00%-Mar 31, 2024
JEFFERIES FINANCIAL GROUP INC.----16,504-100.00%-Mar 31, 2024
FIRST WESTERN TRUST BANK----15,616-100.00%-Mar 31, 2024
CAPITAL FUND MANAGEMENT S.A.----14,700-100.00%-Mar 31, 2024
OAK HILL WEALTH ADVISORS, LLC----12,500-100.00%-Mar 31, 2024
ENTROPY TECHNOLOGIES, LP----11,725-100.00%-Mar 31, 2024
INSPIRE INVESTING, LLC----10,370-100.00%-Mar 31, 2024
BREVAN HOWARD CAPITAL MANAGEMENT LP----9,294-100.00%-Mar 31, 2024
AFFINITY INVESTMENT ADVISORS, LLC----8,886-100.00%-Mar 31, 2024
HOYLECOHEN, LLC----8,775-100.00%-Mar 31, 2024
AE WEALTH MANAGEMENT LLC----8,372-100.00%-Mar 31, 2024
CAXTON ASSOCIATES LP----8,281-100.00%-Mar 31, 2024
CONVERGENCE INVESTMENT PARTNERS, LLC----7,008-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----6,500-100.00%-Mar 31, 2024
EFG ASSET MANAGEMENT (AMERICAS) CORP.----6,496-100.00%-Mar 31, 2024
NEBULA RESEARCH & DEVELOPMENT LLC----6,380-100.00%-Mar 31, 2024
IFRAH FINANCIAL SERVICES, INC.----6,060-100.00%-Mar 31, 2024
CIPHER CAPITAL LP----5,904-100.00%-Mar 31, 2024
EP WEALTH ADVISORS, LLC----5,500-100.00%-Mar 31, 2024
KAPITALO INVESTIMENTOS LTDA----3,593-100.00%-Mar 31, 2024
WALLEYE TRADING LLC----3,000-100.00%-Mar 31, 2024
HEADLANDS TECHNOLOGIES LLC----1,764-100.00%-Mar 31, 2024
JOHNSON FINANCIAL GROUP, INC.----532-100.00%-Mar 31, 2024
ADVISORY SERVICES NETWORK, LLC----529-100.00%-Mar 31, 2024
ROBECO INSTITUTIONAL ASSET MANAGEMENT B.V.----436-100.00%-Mar 31, 2024
SILICON VALLEY CAPITAL PARTNERS----300-100.00%-Mar 31, 2024
POINT72 EUROPE (LONDON) LLP----261-100.00%-Mar 31, 2024
TURTLE CREEK WEALTH ADVISORS, LLC----211-100.00%-Mar 31, 2024
GLASSMAN WEALTH SERVICES----68-100.00%-Mar 31, 2024
M&R CAPITAL MANAGEMENT INC----32-100.00%-Mar 31, 2024
RFP FINANCIAL GROUP LLC----31-100.00%-Mar 31, 2024
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC----15-100.00%-Mar 31, 2024
ROSENBERG MATTHEW HAMILTON----1-100.00%-Mar 31, 2024

Halozyme Therapeutics's largest sold out institutional shareholder by shares sold is DRIEHAUS CAPITAL MANAGEMENT LLC, sold -0.33M shares, valued at -, as of undefined.

Halozyme Therapeutics Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
AMG FUNDS3.38%376,774--Jan 31, 2024
SPARROW FUNDS2.34%8,340--Feb 29, 2024
BANCROFT FUND LTD2.31%3,200,0001,000,00045.45%Dec 29, 2023
ELLSWORTH GROWTH & INCOME FUND LTD2.14%3,000,000700,00030.43%Dec 29, 2023
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC1.89%1,500,000200,00015.38%Dec 29, 2023
GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC1.64%1,300,000--Dec 29, 2023
ELLSWORTH GROWTH & INCOME FUND LTD1.64%2,300,000--Dec 29, 2023
BANCROFT FUND LTD1.59%2,200,000--Dec 29, 2023
Virtus Diversified Income & Convertible Fund1.27%2,590,000--Jan 31, 2024
Fiera Capital Series Trust1.25%24,956--Jun 30, 2023
Virtus Dividend, Interest & Premium Strategy Fund1.20%2,845,000--Jan 31, 2024
Virtus Dividend, Interest & Premium Strategy Fund1.20%2,845,000--Jan 31, 2024
Virtus Equity & Convertible Income Fund1.18%2,330,000--Jan 31, 2024
Virtus Equity & Convertible Income Fund1.18%2,330,000--Jan 31, 2024
Calamos Dynamic Convertible & Income Fund1.05%8,000,000--Jan 31, 2024
Virtus Diversified Income & Convertible Fund0.99%2,020,000--Jan 31, 2024
Virtus Strategy Trust0.96%21,070,000--Dec 29, 2023
Virtus Strategy Trust0.87%19,150,000--Dec 29, 2023
AGF Investments Trust0.86%-30,627--Dec 31, 2023
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND0.81%9,250,000--Jan 31, 2024
CALAMOS CONVERTIBLE & HIGH INCOME FUND0.80%10,000,000--Jan 31, 2024
TETON WESTWOOD FUNDS0.77%500,000100,00025.00%Dec 29, 2023
CALAMOS ADVISORS TRUST/IL0.65%44,000--Dec 31, 2023
CALAMOS ADVISORS TRUST/IL0.65%44,000--Dec 31, 2023
TETON WESTWOOD FUNDS0.62%400,000--Dec 29, 2023
Thrivent ETF Trust0.50%24,793--Dec 31, 2023
Gabelli Healthcare & WellnessRx Trust0.50%60,0008,08115.56%Dec 29, 2023
Virtus Convertible & Income Fund0.49%2,435,000--Jan 31, 2024
Virtus Convertible & Income Fund0.49%2,435,000--Jan 31, 2024
Virtus Convertible & Income Fund II0.49%1,835,000--Jan 31, 2024
Virtus Convertible & Income Fund II0.49%1,835,000--Jan 31, 2024
Virtus Investment Trust0.48%16,420,000--Dec 29, 2023
Virtus Investment Trust0.47%16,055,000--Dec 29, 2023
Virtus Dividend, Interest & Premium Strategy Fund0.45%1,065,000--Jan 31, 2024
Virtus Equity & Convertible Income Fund0.45%885,000--Jan 31, 2024
Federated Hermes Equity Income Fund, Inc.0.44%65,350--Feb 29, 2024
CALAMOS STRATEGIC TOTAL RETURN FUND0.40%4,435,000--Jan 31, 2024
Virtus Diversified Income & Convertible Fund0.38%780,000--Jan 31, 2024
Virtus Strategy Trust0.36%7,865,000--Dec 29, 2023
BlackRock Innovation & Growth Trust0.35%410,430-124,434-23.26%Dec 31, 2023
CALAMOS INVESTMENT TRUST/IL0.34%35,075,000--Jan 31, 2024
HSBC FUNDS0.33%10,710--Jan 31, 2024
Clough Global Equity Fund0.29%18,100--Jan 31, 2024
AB DISCOVERY GROWTH FUND, INC.0.29%431,392-5,185-1.19%Jan 31, 2024
SPDR S&P MIDCAP 400 ETF TRUST0.28%1,070,908-10,074-0.93%Dec 29, 2023
T. Rowe Price Quantitative Management Funds, Inc.0.28%1,009,700-118,800-10.53%Dec 31, 2023
Virtus Strategy Trust0.27%6,005,000--Dec 29, 2023
Virtus Convertible & Income Fund II0.26%970,000--Jan 31, 2024
Virtus Convertible & Income Fund0.25%1,230,000--Jan 31, 2024
DELAWARE GROUP EQUITY FUNDS IV0.24%254,258-17,236-6.35%Dec 29, 2023
LORD ABBETT DEVELOPING GROWTH FUND, INC.0.23%211,900--Jan 31, 2024
BUFFALO FUNDS0.22%472,13423,2105.17%Dec 31, 2023
BNY MELLON MIDCAP INDEX FUND, INC.0.19%81,684-5,219-6.01%Jan 31, 2024
VANGUARD VALLEY FORGE FUNDS0.19%92,464--Dec 31, 2023
BlackRock Advantage SMID Cap Fund, Inc.0.18%33,6772,3457.48%Dec 29, 2023
Federated Hermes MDT Series0.17%429,908286,345199.46%Jan 31, 2024
CALAMOS GLOBAL TOTAL RETURN FUND0.16%375,000--Jan 31, 2024
HARTFORD HLS SERIES FUND II INC0.16%38,589--Dec 31, 2023
Calamos Global Dynamic Income Fund0.13%1,550,000--Jan 31, 2024
VANGUARD EXPLORER FUND0.13%1,596,524143,4869.87%Jan 31, 2024
OBERWEIS FUNDS0.12%96,30045,80090.69%Dec 31, 2023
NUVEEN INVESTMENT TRUST0.09%34,984-693-1.94%Dec 31, 2023
MERIDIAN FUND INC0.08%297,134--Dec 29, 2023
Clough Global Opportunities Fund0.08%32,900--Jan 31, 2024
M FUND INC0.08%37,59610,14936.98%Mar 31, 2024
AMG FUNDS III0.08%12,423--Feb 29, 2024
Federated Hermes Index Trust0.07%16,237-656-3.88%Jan 31, 2024
ALGER FUNDS0.07%69,352--Jan 31, 2024
Total Fund Solution0.07%24,213--Dec 31, 2023
Voya VARIABLE PRODUCTS TRUST0.07%19,912-364-1.80%Dec 31, 2023
VANGUARD ADMIRAL FUNDS0.06%269,191-2,158-0.80%Feb 29, 2024
AMERICAN CENTURY MUTUAL FUNDS, INC.0.06%597,26240,3707.25%Jan 31, 2024
STATE STREET INSTITUTIONAL FUNDS0.06%53,586-3,178-5.60%Dec 31, 2023
Voya PARTNERS INC0.06%4,845,000--Dec 31, 2023
Voya EQUITY TRUST0.06%85,3254,7815.94%Feb 29, 2024
BlackRock Health Sciences Trust II0.06%158,300--Dec 31, 2023
SYNTAX ETF TRUST0.06%1,800-35-1.91%Dec 31, 2023
ALLSPRING VARIABLE TRUST0.05%28,900-500-1.70%Dec 31, 2023
Gabelli Global Small & Mid Cap Value Trust0.05%5,000--Dec 29, 2023
BlackRock Health Sciences Trust0.05%21,055--Dec 31, 2023
DEUTSCHE DWS INVESTMENTS VIT FUNDS0.04%19,7823411.75%Dec 31, 2023
REYNOLDS FUNDS INC0.04%500--Mar 31, 2024
SIT MUTUAL FUNDS INC0.04%14,375-17,300-54.62%Dec 29, 2023
TEKLA HEALTHCARE INVESTORS0.04%48,143--Dec 31, 2023
GABELLI ASSET FUND0.04%15,000--Dec 29, 2023
DSS AMERICAFIRST QUANTITATIVE FUNDS0.04%908--Dec 29, 2023
Humankind Benefit Corp0.04%857688.62%Dec 31, 2023
TEKLA LIFE SCIENCES INVESTORS0.04%21,774--Dec 31, 2023
VIRTUS ALTERNATIVE SOLUTIONS TRUST0.04%147--Jan 31, 2024
TrimTabs ETF Trust0.04%23,76616,919247.10%Jan 31, 2024
QUANTITATIVE MASTER SERIES LLC0.04%236,45816,2487.38%Dec 31, 2023
VICTORY VARIABLE INSURANCE FUNDS0.04%17,640--Dec 31, 2023
GLENMEDE FUND INC0.03%303,653-8,640-2.77%Jan 31, 2024
Nuveen S&P 500 Dynamic Overwrite Fund0.03%1,972--Dec 31, 2023
Capitol Series Trust0.03%311,050138,20079.95%Mar 31, 2024
DELAWARE GROUP EQUITY FUNDS V0.03%1,809,631-7,351-0.40%Feb 29, 2024
AIM INTERNATIONAL MUTUAL FUNDS (INVESCO INTERNATIONAL MUTUAL FUNDS)0.03%1,000,000--Jan 31, 2024
VANGUARD INDEX FUNDS0.03%13,283,8102,057,55818.33%Dec 31, 2023
PRUDENTIAL JENNISON BLEND FUND, INC.0.03%15,848--Feb 29, 2024
ROYCE VALUE TRUST, INC.0.02%29,35329,353-Dec 31, 2023

Halozyme Therapeutics's largest mutual fund holder by % of total assets is "AMG FUNDS", owning 376.77K shares, compromising 3.38% of its total assets.

Halozyme Therapeutics Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 24413-0.96%
31 Dec, 234175.30%
30 Sep, 233965.04%
30 Jun, 23377-2.58%
31 Mar, 23387-10.83%
31 Dec, 2243422.60%
30 Sep, 22354-3.80%
30 Jun, 2236816.09%
31 Mar, 22317-3.06%
31 Dec, 213271.24%
30 Sep, 213231.25%
30 Jun, 21319-6.45%
31 Mar, 21341-0.87%
31 Dec, 2034422.86%
30 Sep, 202801.82%
30 Jun, 2027525.57%
31 Mar, 20219-7.20%
31 Dec, 192363.96%
30 Sep, 192275.58%
30 Jun, 192152.87%
31 Mar, 192093.98%
31 Dec, 182010.50%
30 Sep, 18200-1.96%
30 Jun, 18204-8.52%
31 Mar, 182234.69%
31 Dec, 1721318.99%
30 Sep, 17179-1.65%
30 Jun, 171823.41%
31 Mar, 17176-3.83%
31 Dec, 161836.40%
30 Sep, 16172-1.15%
30 Jun, 16174-0.57%
31 Mar, 16175-0.57%
31 Dec, 15176-5.38%
30 Sep, 1518610.06%
30 Jun, 1516919.01%
31 Mar, 151421.43%
31 Dec, 1414010.24%
30 Sep, 14127-7.30%
30 Jun, 14137-2.84%
31 Mar, 1414110.16%
31 Dec, 1312811.30%
30 Sep, 131152.68%
30 Jun, 13112107.41%
31 Mar, 13545.88%
31 Dec, 12518.51%
30 Sep, 1247-9.62%
30 Jun, 1252-8.77%
31 Mar, 12575.56%
31 Dec, 115431.71%
30 Sep, 114110.81%
30 Jun, 1137-5.13%
31 Mar, 113911.43%
31 Dec, 10359.38%
30 Sep, 10326.67%
30 Jun, 10307.14%
31 Mar, 1028-3.45%
31 Dec, 092952.63%
30 Sep, 0919-26.92%
30 Jun, 092644.44%
31 Mar, 0918-25.00%
31 Dec, 082414.29%
30 Sep, 082131.25%
30 Jun, 08166.67%
31 Mar, 0815-11.76%
31 Dec, 0717-
30 Sep, 0717-5.56%
30 Jun, 071863.64%
31 Mar, 071157.14%
31 Dec, 06716.67%
30 Sep, 066-
30 Jun, 066-
31 Mar, 066100.00%
31 Dec, 053-
30 Sep, 053-
30 Jun, 053-
31 Mar, 05350.00%
31 Dec, 042-

As of 31 Mar 24, 413 institutions are holding Halozyme Therapeutics's shares, representing a decrease of -0.96% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 24122,049,630-1.69%
31 Dec, 23124,144,4992.24%
30 Sep, 23121,421,868-0.34%
30 Jun, 23121,836,738-1.41%
31 Mar, 23123,575,162-3.90%
31 Dec, 22128,590,575-1.66%
30 Sep, 22130,764,7213.03%
30 Jun, 22126,920,6610.52%
31 Mar, 22126,259,874-0.86%
31 Dec, 21127,358,350-0.83%
30 Sep, 21128,425,909-0.18%
30 Jun, 21128,660,532-2.06%
31 Mar, 21131,362,215-3.56%
31 Dec, 20136,209,2251.79%
30 Sep, 20133,814,748-0.90%
30 Jun, 20135,034,6403.44%
31 Mar, 20130,539,8462.56%
31 Dec, 19127,282,7940.81%
30 Sep, 19126,253,9023.23%
30 Jun, 19122,308,2711.11%
31 Mar, 19120,966,4850.10%
31 Dec, 18120,846,652-1.62%
30 Sep, 18122,836,4460.37%
30 Jun, 18122,382,772-0.72%
31 Mar, 18123,274,8270.96%
31 Dec, 17122,106,9730.53%
30 Sep, 17121,459,384-0.41%
30 Jun, 17121,957,3255.85%
31 Mar, 17115,211,7874.11%
31 Dec, 16110,665,1104.41%
30 Sep, 16105,987,8710.87%
30 Jun, 16105,077,2632.37%
31 Mar, 16102,644,6954.35%
31 Dec, 1598,368,871-7.69%
30 Sep, 15106,566,6979.42%
30 Jun, 1597,395,0463.46%
31 Mar, 1594,136,6663.05%
31 Dec, 1491,347,6422.74%
30 Sep, 1488,909,6923.86%
30 Jun, 1485,607,980-0.17%
31 Mar, 1485,756,4778.43%
31 Dec, 1379,089,0631.72%
30 Sep, 1377,753,6653.46%
30 Jun, 1375,152,81460.74%
31 Mar, 1346,753,5297.19%
31 Dec, 1243,618,7541.03%
30 Sep, 1243,172,735-23.13%
30 Jun, 1256,162,40813.27%
31 Mar, 1249,581,53310.70%
31 Dec, 1144,788,863189.53%
30 Sep, 1115,469,583-26.99%
30 Jun, 1121,187,7397.49%
31 Mar, 1119,710,85937.63%
31 Dec, 1014,321,920-10.25%
30 Sep, 1015,957,52211.12%
30 Jun, 1014,360,6087.39%
31 Mar, 1013,372,748-5.44%
31 Dec, 0914,142,09096.29%
30 Sep, 097,204,665-50.65%
30 Jun, 0914,599,64025.57%
31 Mar, 0911,627,029-19.84%
31 Dec, 0814,505,35592.08%
30 Sep, 087,551,757-40.13%
30 Jun, 0812,612,88131.35%
31 Mar, 089,602,70920.10%
31 Dec, 077,995,41910.66%
30 Sep, 077,225,497125.24%
30 Jun, 073,207,881-52.17%
31 Mar, 076,706,500-15.05%
31 Dec, 067,894,45714.56%
30 Sep, 066,891,0004.23%
30 Jun, 066,611,300-0.99%
31 Mar, 066,677,400317.39%
31 Dec, 051,599,800112.51%
30 Sep, 05752,800-81.35%
30 Jun, 054,035,8000.92%
31 Mar, 053,999,00011.02%
31 Dec, 043,602,100-

Halozyme Therapeutics (HALO) has 122.05M shares outstanding as of 31 Mar 24, down -1.69% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 2494.57%1.07%
31 Dec, 2394.07%1.11%
30 Sep, 2392.17%1.13%
30 Jun, 2390.23%1.08%
31 Mar, 2391.52%1.01%
31 Dec, 2295.05%1.04%
30 Sep, 2295.78%1.13%
30 Jun, 2292.01%1.09%
31 Mar, 2291.72%1.12%
31 Dec, 2190.55%1.11%
30 Sep, 2190.43%1.11%
30 Jun, 2190.30%1.00%
31 Mar, 2195.22%0.94%
31 Dec, 20100.82%1.05%
30 Sep, 2097.98%0.99%
30 Jun, 2099.34%1.10%
31 Mar, 2095.16%1.22%
31 Dec, 1988.19%1.18%
30 Sep, 1986.39%1.22%
30 Jun, 1984.11%1.20%
31 Mar, 1983.57%1.18%
31 Dec, 1884.16%1.16%
30 Sep, 1885.33%1.17%
30 Jun, 1885.24%1.14%
31 Mar, 1886.41%1.16%
31 Dec, 1786.16%1.16%
30 Sep, 1786.03%1.04%
30 Jun, 1791.00%1.13%
31 Mar, 1789.58%1.20%
31 Dec, 1686.48%1.26%
30 Sep, 1682.70%1.23%
30 Jun, 1682.12%1.27%
31 Mar, 1680.43%1.33%
31 Dec, 1577.64%1.10%
30 Sep, 1583.96%1.41%
30 Jun, 1577.21%1.37%
31 Mar, 1575.13%1.39%
31 Dec, 1473.51%1.43%
30 Sep, 1471.68%1.50%
30 Jun, 1469.20%1.33%
31 Mar, 1472.10%1.47%
31 Dec, 1370.11%1.47%
30 Sep, 1368.95%1.54%
30 Jun, 1366.81%3.86%
31 Mar, 1341.59%2.70%
31 Dec, 1239.27%2.66%
30 Sep, 1238.44%1.53%
30 Jun, 1250.12%2.36%
31 Mar, 1246.08%2.66%
31 Dec, 1141.63%18.54%
30 Sep, 1114.99%3.52%
30 Jun, 1120.64%5.41%
31 Mar, 1119.53%8.48%
31 Dec, 1015.18%5.23%
30 Sep, 1017.04%6.96%
30 Jun, 1015.65%7.34%
31 Mar, 1014.60%6.13%
31 Dec, 0915.44%23.86%
30 Sep, 098.04%2.60%
30 Jun, 0917.59%8.84%
31 Mar, 0914.11%4.27%
31 Dec, 0818.17%20.54%
30 Sep, 089.41%3.73%
30 Jun, 0815.87%10.55%
31 Mar, 0812.26%10.60%
31 Dec, 0710.76%12.06%
30 Sep, 079.44%49.20%
30 Jun, 074.38%4.77%
31 Mar, 079.58%7.53%
31 Dec, 0611.28%9.35%
30 Sep, 0610.98%9.61%
30 Jun, 0610.69%8.76%
31 Mar, 0611.04%157.73%
31 Dec, 052.65%116.64%
30 Sep, 051.51%2.31%
30 Jun, 058.08%12.42%
31 Mar, 058.07%15.28%
31 Dec, 047.27%-

As of 31 Mar 24, Halozyme Therapeutics is held by 94.57% institutional shareholders, representing a 1.07% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 242150.94%
31 Dec, 2321318.33%
30 Sep, 23180-
30 Jun, 23180-4.26%
31 Mar, 23188-10.90%
31 Dec, 2221115.93%
30 Sep, 22182-13.33%
30 Jun, 2221048.94%
31 Mar, 22141-13.50%
31 Dec, 21163-9.94%
30 Sep, 2118117.53%
30 Jun, 21154-8.88%
31 Mar, 21169-15.08%
31 Dec, 2019957.94%
30 Sep, 20126-22.70%
30 Jun, 2016375.27%
31 Mar, 2093-25.00%
31 Dec, 1912430.53%
30 Sep, 1995-12.04%
30 Jun, 1910818.68%
31 Mar, 1991-6.19%
31 Dec, 189716.87%
30 Sep, 1883-3.49%
30 Jun, 1886-21.10%
31 Mar, 18109-4.39%
31 Dec, 1711431.03%
30 Sep, 1787-18.69%
30 Jun, 1710757.35%
31 Mar, 1768-23.60%
31 Dec, 168920.27%
30 Sep, 1674-3.90%
30 Jun, 1677-21.43%
31 Mar, 169822.50%
31 Dec, 1580-22.33%
30 Sep, 1510327.16%
30 Jun, 1581-2.41%
31 Mar, 158316.90%
31 Dec, 147116.39%
30 Sep, 1461-16.44%
30 Jun, 1473-10.98%
31 Mar, 148228.13%
31 Dec, 136410.34%
30 Sep, 1358-30.12%
30 Jun, 1383137.14%
31 Mar, 133529.63%
31 Dec, 1227-3.57%
30 Sep, 1228-15.15%
30 Jun, 1233-2.94%
31 Mar, 1234-12.82%
31 Dec, 113950.00%
30 Sep, 11268.33%
30 Jun, 1124-7.69%
31 Mar, 112636.84%
31 Dec, 101918.75%
30 Sep, 1016-5.88%
30 Jun, 101713.33%
31 Mar, 1015-16.67%
31 Dec, 091863.64%
30 Sep, 0911-38.89%
30 Jun, 091838.46%
31 Mar, 0913-27.78%
31 Dec, 081820.00%
30 Sep, 08157.14%
30 Jun, 081455.56%
31 Mar, 08912.50%
31 Dec, 078-
30 Sep, 078-42.86%
30 Jun, 071475.00%
31 Mar, 078100.00%
31 Dec, 06433.33%
30 Sep, 063-
30 Jun, 06--100.00%
31 Mar, 063-
31 Dec, 053200.00%
30 Sep, 051-
30 Jun, 051-50.00%
31 Mar, 052-
31 Dec, 042-

215 institutional shareholders have increased their position in HALO stock as of 31 Mar 24 compared to 213 in the previous quarter (a 0.94% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 24139-2.11%
31 Dec, 23142-1.39%
30 Sep, 231449.92%
30 Jun, 23131-13.82%
31 Mar, 23152-13.14%
31 Dec, 2217544.63%
30 Sep, 221218.04%
30 Jun, 22112-9.68%
31 Mar, 221246.90%
31 Dec, 2111624.73%
30 Sep, 2193-13.08%
30 Jun, 21107-17.69%
31 Mar, 2113021.50%
31 Dec, 201078.08%
30 Sep, 209939.44%
30 Jun, 2071-16.47%
31 Mar, 208530.77%
31 Dec, 1965-8.45%
30 Sep, 197118.33%
30 Jun, 1960-3.23%
31 Mar, 19628.77%
31 Dec, 1857-10.94%
30 Sep, 1864-14.67%
30 Jun, 187515.38%
31 Mar, 186514.04%
31 Dec, 175714.00%
30 Sep, 175025.00%
30 Jun, 1740-35.48%
31 Mar, 176229.17%
31 Dec, 1648-5.88%
30 Sep, 1651-3.77%
30 Jun, 165335.90%
31 Mar, 1639-35.00%
31 Dec, 156015.38%
30 Sep, 1552-7.14%
30 Jun, 155643.59%
31 Mar, 153911.43%
31 Dec, 14352.94%
30 Sep, 1434-15.00%
30 Jun, 144021.21%
31 Mar, 1433-13.16%
31 Dec, 133815.15%
30 Sep, 1333106.25%
30 Jun, 131614.29%
31 Mar, 1314-17.65%
31 Dec, 121741.67%
30 Sep, 1212-14.29%
30 Jun, 1214-12.50%
31 Mar, 121660.00%
31 Dec, 111025.00%
30 Sep, 11860.00%
30 Jun, 115-16.67%
31 Mar, 116-33.33%
31 Dec, 109-10.00%
30 Sep, 101011.11%
30 Jun, 109-
31 Mar, 109125.00%
31 Dec, 094-
30 Sep, 094-50.00%
30 Jun, 098300.00%
31 Mar, 092-50.00%
31 Dec, 084100.00%
30 Sep, 082100.00%
30 Jun, 081-66.67%
31 Mar, 083-40.00%
31 Dec, 075-28.57%
30 Sep, 077250.00%
30 Jun, 072-33.33%
31 Mar, 07350.00%
31 Dec, 062-
30 Sep, 06--100.00%
30 Jun, 06350.00%
31 Mar, 062-
31 Dec, 05--100.00%
30 Sep, 051-
30 Jun, 05--
31 Mar, 05--
31 Dec, 04--

139 institutional shareholders have reduced their position in HALO stock as of 31 Mar 24 compared to 142 in the previous quarter (a -2.11% decrease).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 24413-0.96%122,049,630-1.69%94.57%1.07%2150.94%139-2.11%
31 Dec, 234175.30%124,144,4992.24%94.07%1.11%21318.33%142-1.39%
30 Sep, 233965.04%121,421,868-0.34%92.17%1.13%180-1449.92%
30 Jun, 23377-2.58%121,836,738-1.41%90.23%1.08%180-4.26%131-13.82%
31 Mar, 23387-10.83%123,575,162-3.90%91.52%1.01%188-10.90%152-13.14%
31 Dec, 2243422.60%128,590,575-1.66%95.05%1.04%21115.93%17544.63%
30 Sep, 22354-3.80%130,764,7213.03%95.78%1.13%182-13.33%1218.04%
30 Jun, 2236816.09%126,920,6610.52%92.01%1.09%21048.94%112-9.68%
31 Mar, 22317-3.06%126,259,874-0.86%91.72%1.12%141-13.50%1246.90%
31 Dec, 213271.24%127,358,350-0.83%90.55%1.11%163-9.94%11624.73%
30 Sep, 213231.25%128,425,909-0.18%90.43%1.11%18117.53%93-13.08%
30 Jun, 21319-6.45%128,660,532-2.06%90.30%1.00%154-8.88%107-17.69%
31 Mar, 21341-0.87%131,362,215-3.56%95.22%0.94%169-15.08%13021.50%
31 Dec, 2034422.86%136,209,2251.79%100.82%1.05%19957.94%1078.08%
30 Sep, 202801.82%133,814,748-0.90%97.98%0.99%126-22.70%9939.44%
30 Jun, 2027525.57%135,034,6403.44%99.34%1.10%16375.27%71-16.47%
31 Mar, 20219-7.20%130,539,8462.56%95.16%1.22%93-25.00%8530.77%
31 Dec, 192363.96%127,282,7940.81%88.19%1.18%12430.53%65-8.45%
30 Sep, 192275.58%126,253,9023.23%86.39%1.22%95-12.04%7118.33%
30 Jun, 192152.87%122,308,2711.11%84.11%1.20%10818.68%60-3.23%
31 Mar, 192093.98%120,966,4850.10%83.57%1.18%91-6.19%628.77%
31 Dec, 182010.50%120,846,652-1.62%84.16%1.16%9716.87%57-10.94%
30 Sep, 18200-1.96%122,836,4460.37%85.33%1.17%83-3.49%64-14.67%
30 Jun, 18204-8.52%122,382,772-0.72%85.24%1.14%86-21.10%7515.38%
31 Mar, 182234.69%123,274,8270.96%86.41%1.16%109-4.39%6514.04%
31 Dec, 1721318.99%122,106,9730.53%86.16%1.16%11431.03%5714.00%
30 Sep, 17179-1.65%121,459,384-0.41%86.03%1.04%87-18.69%5025.00%
30 Jun, 171823.41%121,957,3255.85%91.00%1.13%10757.35%40-35.48%
31 Mar, 17176-3.83%115,211,7874.11%89.58%1.20%68-23.60%6229.17%
31 Dec, 161836.40%110,665,1104.41%86.48%1.26%8920.27%48-5.88%
30 Sep, 16172-1.15%105,987,8710.87%82.70%1.23%74-3.90%51-3.77%
30 Jun, 16174-0.57%105,077,2632.37%82.12%1.27%77-21.43%5335.90%
31 Mar, 16175-0.57%102,644,6954.35%80.43%1.33%9822.50%39-35.00%
31 Dec, 15176-5.38%98,368,871-7.69%77.64%1.10%80-22.33%6015.38%
30 Sep, 1518610.06%106,566,6979.42%83.96%1.41%10327.16%52-7.14%
30 Jun, 1516919.01%97,395,0463.46%77.21%1.37%81-2.41%5643.59%
31 Mar, 151421.43%94,136,6663.05%75.13%1.39%8316.90%3911.43%
31 Dec, 1414010.24%91,347,6422.74%73.51%1.43%7116.39%352.94%
30 Sep, 14127-7.30%88,909,6923.86%71.68%1.50%61-16.44%34-15.00%
30 Jun, 14137-2.84%85,607,980-0.17%69.20%1.33%73-10.98%4021.21%
31 Mar, 1414110.16%85,756,4778.43%72.10%1.47%8228.13%33-13.16%
31 Dec, 1312811.30%79,089,0631.72%70.11%1.47%6410.34%3815.15%
30 Sep, 131152.68%77,753,6653.46%68.95%1.54%58-30.12%33106.25%
30 Jun, 13112107.41%75,152,81460.74%66.81%3.86%83137.14%1614.29%
31 Mar, 13545.88%46,753,5297.19%41.59%2.70%3529.63%14-17.65%
31 Dec, 12518.51%43,618,7541.03%39.27%2.66%27-3.57%1741.67%
30 Sep, 1247-9.62%43,172,735-23.13%38.44%1.53%28-15.15%12-14.29%
30 Jun, 1252-8.77%56,162,40813.27%50.12%2.36%33-2.94%14-12.50%
31 Mar, 12575.56%49,581,53310.70%46.08%2.66%34-12.82%1660.00%
31 Dec, 115431.71%44,788,863189.53%41.63%18.54%3950.00%1025.00%
30 Sep, 114110.81%15,469,583-26.99%14.99%3.52%268.33%860.00%
30 Jun, 1137-5.13%21,187,7397.49%20.64%5.41%24-7.69%5-16.67%
31 Mar, 113911.43%19,710,85937.63%19.53%8.48%2636.84%6-33.33%
31 Dec, 10359.38%14,321,920-10.25%15.18%5.23%1918.75%9-10.00%
30 Sep, 10326.67%15,957,52211.12%17.04%6.96%16-5.88%1011.11%
30 Jun, 10307.14%14,360,6087.39%15.65%7.34%1713.33%9-
31 Mar, 1028-3.45%13,372,748-5.44%14.60%6.13%15-16.67%9125.00%
31 Dec, 092952.63%14,142,09096.29%15.44%23.86%1863.64%4-
30 Sep, 0919-26.92%7,204,665-50.65%8.04%2.60%11-38.89%4-50.00%
30 Jun, 092644.44%14,599,64025.57%17.59%8.84%1838.46%8300.00%
31 Mar, 0918-25.00%11,627,029-19.84%14.11%4.27%13-27.78%2-50.00%
31 Dec, 082414.29%14,505,35592.08%18.17%20.54%1820.00%4100.00%
30 Sep, 082131.25%7,551,757-40.13%9.41%3.73%157.14%2100.00%
30 Jun, 08166.67%12,612,88131.35%15.87%10.55%1455.56%1-66.67%
31 Mar, 0815-11.76%9,602,70920.10%12.26%10.60%912.50%3-40.00%
31 Dec, 0717-7,995,41910.66%10.76%12.06%8-5-28.57%
30 Sep, 0717-5.56%7,225,497125.24%9.44%49.20%8-42.86%7250.00%
30 Jun, 071863.64%3,207,881-52.17%4.38%4.77%1475.00%2-33.33%
31 Mar, 071157.14%6,706,500-15.05%9.58%7.53%8100.00%350.00%
31 Dec, 06716.67%7,894,45714.56%11.28%9.35%433.33%2-
30 Sep, 066-6,891,0004.23%10.98%9.61%3---100.00%
30 Jun, 066-6,611,300-0.99%10.69%8.76%--100.00%350.00%
31 Mar, 066100.00%6,677,400317.39%11.04%157.73%3-2-
31 Dec, 053-1,599,800112.51%2.65%116.64%3200.00%--100.00%
30 Sep, 053-752,800-81.35%1.51%2.31%1-1-
30 Jun, 053-4,035,8000.92%8.08%12.42%1-50.00%--
31 Mar, 05350.00%3,999,00011.02%8.07%15.28%2---
31 Dec, 042-3,602,100-7.27%-2---

Halozyme Therapeutics Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.49$384.89K168,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.35$383.50K168,176

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.49$384.89K168,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.35$383.50K168,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERM-ExemptSell10,000$8.11$81.10K51,715
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERM-ExemptSell10,000$8.11$81.10K41,715

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Apr 29, 2024Posard Matthew L.director-A-AwardBuy6,501--119,755
Apr 29, 2024Posard Matthew L.director-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024Miyashita Akiko Monidirector-A-AwardBuy6,501--20,772
Apr 29, 2024Miyashita Akiko Monidirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024MATSUI CONNIEdirector-A-AwardBuy6,501--193,505
Apr 29, 2024MATSUI CONNIEdirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024Krishnan Maheshdirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024Krishnan Maheshdirector-A-AwardBuy6,501--6,501
Apr 29, 2024Henderson Jeffrey Williamdirector-A-AwardBuy6,501--53,611
Apr 29, 2024Henderson Jeffrey Williamdirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024Duncan Barbara Gayledirector-A-AwardBuy6,501--15,754
Apr 29, 2024Duncan Barbara Gayledirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 29, 2024Connaughton Bernadettedirector-A-AwardBuy6,501--46,787
Apr 29, 2024Connaughton Bernadettedirector-A-AwardBuy8,804$38.46$338.60K8,804
Apr 25, 2024Krishnan Mahesh-Buy----
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERM-ExemptBuy10,000$8.11$81.10K178,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.49$384.89K168,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERS-SaleSell10,000$38.35$383.50K168,176
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERM-ExemptSell10,000$8.11$81.10K51,715
Apr 17, 2024LaBarre Michael J.officer SVP, CHIEF TECHNICAL OFFICERM-ExemptSell10,000$8.11$81.10K41,715

The last insider sell of Halozyme Therapeutics's stock was made by LaBarre Michael J. on Apr 17 2024, selling 10,000 shares at $38.49 per share (valued at $384.89K).

Halozyme Therapeutics Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 20241425.00%
Q1 2024324571.11%
Q4 202361346.15%
Q3 202392931.03%
Q2 2023184450.00%
Q1 2023265349.06%
Q4 20222238.70%
Q2 20227--
Q1 2022202774.07%
Q4 202141136.36%
Q3 202161833.33%
Q2 2021121675.00%
Q1 2021213756.76%
Q4 20201156.67%
Q3 20201911.11%
Q2 2020103333.33%
Q1 2020273284.38%
Q4 20191250.00%
Q3 2019-3-
Q2 2019126200.00%

1 total buy trades, and 4 total sell trades (buy/sell ratio of 0.25%) were made by Halozyme Therapeutics's insiders, as of Q2 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q2 2024-2-
Q1 2024-6-
Q4 2023-6-
Q3 2023-14-
Q2 2023-2-
Q1 2023-19-
Q4 2022-15-
Q2 2022---
Q1 2022---
Q4 2021-7-
Q3 2021-11-
Q2 2021-9-
Q1 2021-12-
Q4 2020-13-
Q3 2020-5-
Q2 2020-1-
Q1 20203--
Q4 2019---
Q3 2019-1-
Q2 2019---

As of Q2 2024, Insider owners conducted 0 open market buy trades and 2 open market sell trades of Halozyme Therapeutics's stocks.

Halozyme Therapeutics Peer Ownership


TickerCompany
DICEDICE Therapeutics, Inc.
CERECerevel Therapeutics Holdings, Inc.
BMRNBioMarin Pharmaceutical Inc.
BGNEBeiGene, Ltd.
VRDNViridian Therapeutics, Inc.
INBXInhibrx, Inc.
ALNYAlnylam Pharmaceuticals, Inc.
EWTXEdgewise Therapeutics, Inc.
BPMCBlueprint Medicines Corporation
LEGNLegend Biotech Corporation
LRMRLarimar Therapeutics, Inc.
ALECAlector, Inc.
EXELExelixis, Inc.
APLSApellis Pharmaceuticals, Inc.
INSMInsmed Incorporated
PTGXProtagonist Therapeutics, Inc.
CYTKCytokinetics, Incorporated
ASNDAscendis Pharma A/S
RAREUltragenyx Pharmaceutical Inc.
AGIOAgios Pharmaceuticals, Inc.

HALO Ownership FAQ


Halozyme Therapeutics is owned by institutional shareholders (94.57%), insiders (1.11%), and public (4.31%). The largest institutional shareholder of Halozyme Therapeutics is BLACKROCK INC. (14.13% of total shares) and the top mutual fund owner is AMG FUNDS (3.38% of total shares).

Halozyme Therapeutics's major institutional shareholders are BLACKROCK INC., VANGUARD GROUP INC, STATE STREET CORP, SNYDER CAPITAL MANAGEMENT L P, and ARTISAN PARTNERS LIMITED PARTNERSHIP. The top five shareholders own together 35.40% of the company's share outstanding.

As of Mar 2024, there are 413 institutional shareholders of Halozyme Therapeutics.

BLACKROCK INC owns 18.24M shares of Halozyme Therapeutics, representing 14.13% of the company's total shares outstanding, valued at $742.07M (as of Mar 2024).

As of Mar 2024, VANGUARD GROUP INC holds 13.05M shares of Halozyme Therapeutics (HALO), compromising 10.11% of the company, valued at $530.84M.

STATE STREET CORP is the third largest holder of Halozyme Therapeutics. The company owns 6.49M of the company's shares outstanding (worth $263.9M).